NZ patients get new funded option for treatment-resistant depression
This article was originally published in Scrip
Executive Summary
Patients suffering from severe depression in New Zealand now have access to Merck's Avanza (mirtazapine), after the country's pharmaceutical management agency Pharmac began funding the drug on November 1st.